Official announcements (8-K)

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

In the company's wordsOn November 2, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and nine months ended September 30, 2026. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of …

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

In the company's words(d) On October 20, 2026, Daniel Brennan was appointed as a new member of the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”). In connection with the appointment of Mr. Brennan, the size of the Board was increased from ten to eleven members. Mr. Brennan also has joined our Audit and Finance Committee. Mr. Brennan served as the Executive Vice President, Chief Financial Officer of Boston Scientific Corporation, a medical device and healthcare technology company, from January 2014 until his retirement in June 2025. He was the Senior Vice President, Corporate Controller from 2010 through 2013 and, prior to that role, he held various …

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

In the company's wordsOn August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”). In connection with Mr. Poole’s appointment, Charles F. Wagner, Jr., the Company’s Executive Vice President and Chief Operating & Financial Officer, will cease serving as Chief Financial Officer as of the Effective Date, but will remain Executive Vice President and Chief Operating Officer. Mr. Poole, 51, has been Senior Vice President, Finance at the Company since March 2020. Previously, Mr. Poole served as Chief Financial Officer of Evelo Biosciences, Inc. …

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

In the company's wordsOn August 3, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and six months ended June 30, 2026. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as …

Signed a major agreement (Item 1.01)

A major new contract can change what the company sells, spends or owes.

In the company's wordsEntry into a Material Definitive Agreement. Merger Agreement On July 6, 2026, Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (“Parent”), Clark Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and Crinetics Pharmaceuticals, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”). Subject to the terms of the Merger Agreement, Merger Sub will be merged with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Capitalized terms used herein and not otherwise defined herein have the meanings …

Shared information with investors (Item 7.01)

Information shared with investors, often a presentation or press release.

In the company's wordsOn July 6, 2026, Parent held a conference call, commencing at 4:30 p.m. Eastern time, to its investors, which included an investor presentation. A copy of the investor presentation is attached hereto as Exhibit 99.1. The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such filing.

Announced another event (Item 8.01)

Another event the company chose to report publicly.

In the company's wordsOn July 6, 2026, the Company and Parent issued a joint press release announcing the execution of the Merger Agreement. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference. Cautionary Notice Regarding Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 related to the Company, Parent and the Transactions that are subject to risks, uncertainties and other factors. While Parent believes the forward-looking statements contained in this Current Report on Form 8-K are accurate, these forward-looking statements …

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

In the company's wordsOn March 27, 2026, the Board of Directors (the "Board") of Vertex Pharmaceuticals Incorporated (the "Company") approved the Vertex Pharmaceuticals Incorporated 2026 Stock and Option Plan (the "2026 Plan"), which replaces the Vertex Pharmaceuticals Incorporated 2013 Stock and Option Plan, subject to shareholder approval. A summary of the principal features of the Plan is set forth under Proposal No. 4 of the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 2, 2026 (the “Proxy Statement”), which description is incorporated herein by reference. The Plan was approved by the Company's shareholders at the Company's annual meeting …

Shared shareholder vote results (Item 5.07)

How shareholders voted on board members and proposals.

In the company's wordsThe Annual Meeting was held on May 13, 2026. Set forth below are the voting results for each of the proposals submitted to a vote of the Company's shareholders at the Annual Meeting: Proposal No. 1: Based upon the following votes, the shareholders elected Sangeeta Bhatia, Lloyd Carney, Alan Garber, Reshma Kewalramani, Michel Lagarde, Jeffrey Leiden, Diana McKenzie, Bruce Sachs, Jennifer Schneider and Nancy Thornberry to serve as members of the Company's Board of Directors until the annual meeting of shareholders to be held in 2027: For Against Abstain Non-Votes Sangeeta Bhatia 221,280,173 1,624,141 93,322 10,337,217 Lloyd Carney 213,048,550 9,855,369 93,717 10,337,217 …

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

In the company's wordsOn May 4, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three months ended March 31, 2026. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or …

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

In the company's wordsOn April 28, 2026, Suketu Upadhyay informed the board of directors (the “Board”) of Vertex Pharmaceuticals Incorporated (the “Company”) of his decision not to stand for re-election as a director of the Company at the Company’s 2026 annual meeting of shareholders (the “2026 Annual Meeting”). Mr. Upadhyay has recently been named the forthcoming Chief Financial Officer of Incyte Corporation. Mr. Upadhyay will continue to serve on the Board until the time of the 2026 Annual Meeting. Mr. Upadhyay’s decision to depart from the Board was due to scheduling conflicts associated with his new role at Incyte Corporation and did not involve any disagreement with the Company on any …

Announced another event (Item 8.01)

Another event the company chose to report publicly.

In the company's wordsVertex Pharmaceuticals Incorporated (the “Company”) has completed the submission to the U.S. Food and Drug Administration (the “FDA”) of its rolling Biologics Licensing Application (“BLA”) for potential accelerated approval of povetacicept for the treatment of immunoglobulin A nephropathy (“IgAN”) in adults. The Company used a priority review voucher and therefore expects the FDA review of the povetacicept BLA to be expedited to six months from the date of the FDA’s acceptance of the BLA versus the typical ten-month review. Special Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements that are subject to risks, …

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

In the company's wordsOn February 12, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and twelve months ended December 31, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of …

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

In the company's wordsOn November 3, 2025, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and nine months ended September 30, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of …

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

In the company's wordsOn August 4, 2025, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and six months ended June 30, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as …

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

In the company's wordsOn August 4, 2025, the Company announced the retirement of David Altshuler, Executive Vice President and Chief Scientific Officer, effective August 1, 2026.

Announced another event (Item 8.01)

Another event the company chose to report publicly.

Shared shareholder vote results (Item 5.07)

How shareholders voted on board members and proposals.

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

Announced another event (Item 8.01)

Another event the company chose to report publicly.

Shared financial results (Item 2.02)

New results: figures on this page will update when the full quarterly or annual report is filed.

Change in its leaders or board (Item 5.02)

New leaders or board members can bring a change in strategy.

Shared information with investors (Item 7.01)

Information shared with investors, often a presentation or press release.